BioCentury | Feb 5, 2015
Finance

PPPs holding steady

...of Technology (founder) University Edinburgh Molecular Imaging Ltd. Diagnostic U.K. University of Edinburgh (launched) University Glionova AB...
BioCentury | Dec 15, 2014
Emerging Company Profile

No escape for GBM

...demonstrated a survival benefit but could result in resistance because they target specific genetic mutations. Glionova...
...of just 26 days. The data were published in Cell in April. The same week Glionova...
...preclinical data they have ever seen," he added. Steiner said the series A should allow Glionova...
BioCentury | Nov 24, 2014
Finance

Glionova's head start

...Thanks to an ex-industry team working within a research institute, Glionova AB has a head start compared...
...a preclinical brain cancer compound licensed from the Karolinska Institute . The cash will allow Glionova...
...trial to treat glioblastoma multiforme (GBM) at the start of 2016. Eugen Steiner, CEO of Glionova...
BioCentury | Nov 24, 2014
Company News

Glionova Therapeutics board of directors update

Glionova Therapeutics , Stockholm, Sweden Business: Cancer Appointed: Johan Christenson, partner at HealthCap; and Nanna Lueneborg, investment director at Novo Seeds at Novo A/S WIR Staff cancer...
BioCentury | Nov 17, 2014
Financial News

Glionova Therapeutics completes venture financing

Glionova Therapeutics , Stockholm, Sweden Business: Cancer Date completed: 2014-11-12 Type: Venture financing Raised: SEK42 million ($5.7 million) Investors: Novo Seeds; HealthCap WIR Staff cancer...
Items per page:
1 - 5 of 5
BioCentury | Feb 5, 2015
Finance

PPPs holding steady

...of Technology (founder) University Edinburgh Molecular Imaging Ltd. Diagnostic U.K. University of Edinburgh (launched) University Glionova AB...
BioCentury | Dec 15, 2014
Emerging Company Profile

No escape for GBM

...demonstrated a survival benefit but could result in resistance because they target specific genetic mutations. Glionova...
...of just 26 days. The data were published in Cell in April. The same week Glionova...
...preclinical data they have ever seen," he added. Steiner said the series A should allow Glionova...
BioCentury | Nov 24, 2014
Finance

Glionova's head start

...Thanks to an ex-industry team working within a research institute, Glionova AB has a head start compared...
...a preclinical brain cancer compound licensed from the Karolinska Institute . The cash will allow Glionova...
...trial to treat glioblastoma multiforme (GBM) at the start of 2016. Eugen Steiner, CEO of Glionova...
BioCentury | Nov 24, 2014
Company News

Glionova Therapeutics board of directors update

Glionova Therapeutics , Stockholm, Sweden Business: Cancer Appointed: Johan Christenson, partner at HealthCap; and Nanna Lueneborg, investment director at Novo Seeds at Novo A/S WIR Staff cancer...
BioCentury | Nov 17, 2014
Financial News

Glionova Therapeutics completes venture financing

Glionova Therapeutics , Stockholm, Sweden Business: Cancer Date completed: 2014-11-12 Type: Venture financing Raised: SEK42 million ($5.7 million) Investors: Novo Seeds; HealthCap WIR Staff cancer...
Items per page:
1 - 5 of 5